alternatives to glp-1 Top 5 Natural You Might Consider Tired of GLP-1s? Comparing Gastric

Lingvay, I., Catarig, A

5e), adipose tissue mass (Extended Data Fig

In 2025, Novo Nordisks semaglutide awaits several first-time FDA decisions: 3Q 2025 the first GLP-1 (Wegovy) for metabolic dysfunction-associated steatohepatitis (MASH) 4Q 2025 the first oral GLP-1 ( oral formulation of Wegovy 25 mg ) for weight loss and weight loss plus secondary CV risk reduction 4Q 2025 Wegovy for heart failure with preserved ejection fraction and obesity October 2025 new indication for oral Rybelsus for secondary CV risk reduction 2025 Ozempic for T2DM and peripheral artery disease (PAD) Given the considerable continued growth expected in the GLP-1 pipeline, Prime Therapeutics (Prime) talented team of clinical experts actively monitors this emerging landscape

Virz GM, et al

Nonetheless, reports indicate that staffing remains tight: many new GLP-1 projects have been reported lagging simply because qualified managers and operators are scarce, especially in regions like North Carolina and Indiana where fabs are multiplying simultaneously